Background. Clinical trials have previously shown the benefits of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections in the treatment of type 1 diabetes. The benefits in clinical practice are less clear and this study was designed to compare glycaemic parameters using CGMS before and after commencement of CSII. Aim. To assess changes in the following after CSII is commenced: average blood glucose (BG), glucose variability, duration of hyperglycaemia and hypoglycaemia, HbA1c, weight and insulin dosages changes. Methods. All patients with type 1 diabetes commencing CSII between February 2009 and February 2010 at the Baker IDI Heart and Diabetes Institute were asked to wear a CGMS device (Medtronic Minimed MMT -7102) prior to and 3 months post CSII start. Medical records of the patients were reviewed retrospectively for weight, HbA1c and insulin doses. The data were analysed using paired t-test (SPSS version 19 software, SPSS Inc., 2010) for the mean difference before and after insulin pump start. Results. From the 22 patients, 8 had incomplete CGMS data and were excluded. The remaining 14 patients consisted of 6 female and 8 male, and had a mean age of 45.4 years, mean duration of diabetes 16.1 years (ranged 4 - 28 years). From CGMS results, the mean of variables are displayed in Table 1. Conclusion. In a clinical practice setting commencing CSII was associated with improved HbA1c, reduced glycaemic variability, lower insulin doses and weight loss in this small study. There was no associated increase in hypoglycaemia despite significantly improved glycaemic control. These results are consistent with clinical trial data and are likely to lead to improved outcomes and quality of life in the long term.